Quantum-Si (QSI) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 07, 2024
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-39486
Entity Registrant Name	QUANTUM-SI INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1388175
Entity Address, Address Line One	29 Business Park Drive
Entity Address, City or Town	Branford
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06405
City Area Code	866
Local Phone Number	688-7374
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001816431
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Class A common stock
Entity Listings [Line Items]
Title of 12(b) Security	Class A common stock, $0.0001 per share
Trading Symbol	QSI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		122,775,352
Redeemable Warrants
Entity Listings [Line Items]
Title of 12(b) Security	Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	QSIAW
Security Exchange Name	NASDAQ
Class B common stock
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		19,937,500

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 42,268	$ 133,860
Marketable securities	154,076	123,876
Accounts receivable, net of allowance of $0 and $0, respectively	1,022	368
Inventory	4,091	3,945
Prepaid expenses and other current assets	4,371	4,261
Total current assets	205,828	266,310
Property and equipment, net	16,254	16,275
Internally developed software, net	0	532
Operating lease right-of-use assets	13,677	14,438
Other assets	695	695
Total assets	236,454	298,250
Current liabilities:
Accounts payable	2,153	1,766
Accrued payroll and payroll-related costs	4,603	4,943
Accrued contracted services	2,133	1,519
Accrued expenses and other current liabilities	2,839	1,815
Current portion of operating lease liabilities	3,614	1,566
Total current liabilities	15,342	11,609
Warrant liabilities	357	1,274
Operating lease liabilities	24	11
Other long-term liabilities	10,211	13,737
Total liabilities	25,934	26,631
Commitments and contingencies (Note 15)
Stockholders’ equity
Additional paid-in capital	773,873	767,239
Accumulated other comprehensive loss	153	0
Accumulated deficit	(563,520)	(495,634)
Total stockholders’ equity	210,520	271,619
Total liabilities and stockholders’ equity	236,454	298,250
Class A common stock
Stockholders’ equity
Common stock	12	12
Class B common stock
Stockholders’ equity
Common stock	$ 2	$ 2

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Allowance for estimated credit losses	$ 0	$ 0
Class A common stock
Stockholders’ equity
Common stock, Par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares, issued	122,775,352	121,832,417
Common stock, shares, outstanding	122,775,352	121,832,417
Class B common stock
Stockholders’ equity
Common stock, Par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	27,000,000	27,000,000
Common stock, shares, issued	19,937,500	19,937,500
Common stock, shares, outstanding	19,937,500	19,937,500

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Revenue:	$ 787	$ 223	$ 1,866	$ 682
Cost of revenue	420	115	876	372
Gross profit	367	108	990	310
Operating expenses:
Research and development	16,171	16,587	42,653	50,588
Selling, general and administrative	12,284	10,696	36,236	33,010
Total operating expenses	28,455	27,283	78,889	83,598
Loss from operations	(28,088)	(27,175)	(77,899)	(83,288)
Dividend and interest income	2,688	2,572	9,149	7,274
Unrealized gain on trading securities	0	1,953	0	8,302
Realized loss on trading securities	0	(1,901)	0	(6,489)
Change in fair value of warrant liabilities	121	(162)	917	(81)
Other income (expense), net	9	(15)	(10)	370
Loss before provision for income taxes	(25,270)	(24,728)	(67,843)	(73,912)
Provision for income taxes	(43)	0	(43)	0
Net loss	$ (25,313)	$ (24,728)	$ (67,886)	$ (73,912)
Basic net loss per share (in dollars per share)	$ (0.18)	$ (0.17)	$ (0.48)	$ (0.52)
Diluted net loss per share (in dollars per share)	$ (0.18)	$ (0.17)	$ (0.48)	$ (0.52)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic (in shares)	142,399	141,660	142,039	141,154
Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted (in shares)	142,399	141,660	142,039	141,154
Other comprehensive gain (loss):
Net unrealized gain on marketable securities, net of tax	$ 163	$ 0	$ 163	$ 0
Foreign currency translation adjustment	(3)	0	(10)	0
Total other comprehensive gain, net of tax	160	0	153	0
Comprehensive loss	(25,153)	(24,728)	(67,733)	(73,912)
Product
Revenue:
Revenue:	764	216	1,776	654
Service
Revenue:
Revenue:	$ 23	$ 7	$ 90	$ 28

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Class A common stock	Class B common stock	Common Stock Class A common stock	Common Stock Class B common stock	Additional paid-in capital	Accumulated other comprehensive (loss) gain	Accumulated deficit
Balance at Dec. 31, 2022	$ 358,706			$ 12	$ 2	$ 758,366		$ (399,674)
Balance (in shares) at Dec. 31, 2022				120,006,757	19,937,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options and vesting of restricted stock units (in shares)				1,552,583
Stock-based compensation	3,908					3,908
Net loss	(23,611)							(23,611)
Balance (in shares) at Mar. 31, 2023				121,559,340	19,937,500
Balance at Mar. 31, 2023	339,003			$ 12	$ 2	762,274		(423,285)
Balance at Dec. 31, 2022	358,706			$ 12	$ 2	758,366		(399,674)
Balance (in shares) at Dec. 31, 2022				120,006,757	19,937,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain (loss) on marketable securities, net of tax	0
Foreign currency translation	0
Net loss	(73,912)
Balance (in shares) at Sep. 30, 2023				121,790,534	19,937,500
Balance at Sep. 30, 2023	292,065			$ 12	$ 2	765,637		(473,586)
Balance at Mar. 31, 2023	339,003			$ 12	$ 2	762,274		(423,285)
Balance (in shares) at Mar. 31, 2023				121,559,340	19,937,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options and vesting of restricted stock units (in shares)				74,273
Stock-based compensation	1,865					1,865
Net loss	(25,573)							(25,573)
Balance (in shares) at Jun. 30, 2023				121,633,613	19,937,500
Balance at Jun. 30, 2023	315,295			$ 12	$ 2	764,139		(448,858)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options and vesting of restricted stock units (in shares)				156,921
Common stock issued upon exercise of stock options and vesting of restricted stock units	357					357
Stock-based compensation	1,141					1,141
Net unrealized gain (loss) on marketable securities, net of tax	0
Foreign currency translation	0
Net loss	(24,728)							(24,728)
Balance (in shares) at Sep. 30, 2023				121,790,534	19,937,500
Balance at Sep. 30, 2023	292,065			$ 12	$ 2	765,637		(473,586)
Balance at Dec. 31, 2023	271,619			$ 12	$ 2	767,239	$ 0	(495,634)
Balance (in shares) at Dec. 31, 2023		121,832,417	19,937,500	121,832,417	19,937,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon vesting of restricted stock units (in shares)				46,572
Stock-based compensation	1,645					1,645
Net unrealized gain (loss) on marketable securities, net of tax	(28)						(28)
Refund of issuance costs from 2021 Business Combination	14					14
Foreign currency translation	(5)						(5)
Net loss	(19,474)							(19,474)
Balance (in shares) at Mar. 31, 2024				121,878,989	19,937,500
Balance at Mar. 31, 2024	253,771			$ 12	$ 2	768,898	(33)	(515,108)
Balance at Dec. 31, 2023	271,619			$ 12	$ 2	767,239	0	(495,634)
Balance (in shares) at Dec. 31, 2023		121,832,417	19,937,500	121,832,417	19,937,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain (loss) on marketable securities, net of tax	163
Foreign currency translation	(10)
Net loss	(67,886)
Balance (in shares) at Sep. 30, 2024		122,775,352	19,937,500	122,775,352	19,937,500
Balance at Sep. 30, 2024	210,520			$ 12	$ 2	773,873	153	(563,520)
Balance at Mar. 31, 2024	253,771			$ 12	$ 2	768,898	(33)	(515,108)
Balance (in shares) at Mar. 31, 2024				121,878,989	19,937,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon vesting of restricted stock units (in shares)				407,274
Common stock issued upon exercise of stock options (in shares)				96,069
Common stock issued upon exercise of stock options	136					136
Stock-based compensation	2,426					2,426
Net unrealized gain (loss) on marketable securities, net of tax	28						28
Foreign currency translation	(2)						(2)
Net loss	(23,099)							(23,099)
Balance (in shares) at Jun. 30, 2024				122,382,332	19,937,500
Balance at Jun. 30, 2024	233,260			$ 12	$ 2	771,460	(7)	(538,207)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon vesting of restricted stock units (in shares)				351,550
Common stock issued upon exercise of stock options (in shares)				41,470
Common stock issued upon exercise of stock options	2					2
Stock-based compensation	2,411					2,411
Net unrealized gain (loss) on marketable securities, net of tax	163						163
Foreign currency translation	(3)						(3)
Net loss	(25,313)							(25,313)
Balance (in shares) at Sep. 30, 2024		122,775,352	19,937,500	122,775,352	19,937,500
Balance at Sep. 30, 2024	$ 210,520			$ 12	$ 2	$ 773,873	$ 153	$ (563,520)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (67,886)	$ (73,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,606	3,063
Non-cash lease expense	1,808	1,486
Unrealized (gain) loss on trading securities, net	0	(8,302)
Realized (gain) loss on trading securities, net	0	6,489
(Accretion) amortization on marketable securities	(6,517)	0
Gain on disposal of fixed assets	0	(8)
Write-down of inventory	2,391	0
Change in fair value of warrant liabilities	(917)	81
Change in fair value of contingent consideration	0	(400)
Stock-based compensation	6,482	6,914
Other	23	0
Changes in operating assets and liabilities:
Accounts receivable, net	(654)	(466)
Inventory	(1,625)	(2,325)
Prepaid expenses and other current assets	(545)	(236)
Operating lease right-of-use assets	0	(83)
Other assets	0	(4)
Accounts payable	89	(732)
Accrued expenses and other current liabilities	1,343	(2,656)
Other long-term liabilities	(2,525)	19
Operating lease liabilities	13	(1,995)
Net cash used in operating activities	(64,914)	(73,067)
Cash flows from investing activities:
Purchases of property and equipment	(3,148)	(4,877)
Internally developed software - capitalized costs	(59)	(763)
Purchases of marketable securities	(262,043)	0
Sales and maturities of marketable securities	238,500	88,000
Net cash (used in) provided by investing activities	(26,750)	82,360
Cash flows from financing activities:
Proceeds from exercise of stock options	138	357
Deferred offering costs	(70)	(147)
Refund of issuance costs from 2021 Business Combination	14	0
Net cash provided by financing activities	82	210
Effect of exchange rate changes on cash and cash equivalents	(10)	0
Net (decrease) increase in cash and cash equivalents	(91,592)	9,503
Cash and cash equivalents at beginning of period	133,860	84,319
Cash and cash equivalents at end of period	42,268	93,822
Noncash Investing and Financing Items [Abstract]
Property and equipment purchased but not paid	497	59
Deferred offering costs payable	$ 75	$ 136

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Quantum-Si Incorporated (including its subsidiaries, the “Company” or “Quantum-Si”) was incorporated in Delaware on June 10, 2020 as HighCape Capital Acquisition Corp. (“HighCape”). The Company’s legal name became Quantum-Si Incorporated following a business combination on June 10, 2021 between the Company and Q-SI Operations Inc. (formerly Quantum-Si Incorporated) (the “Business Combination”), which was founded in 2013. The Company is an innovative life sciences company with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. The Company has developed a proprietary universal single-molecule detection platform that the Company is first applying to proteomics to enable Next-Generation Protein Sequencing ™ (“NGPS”), the ability to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), and can be used for the study of nucleic acids. The Company’s platform is currently comprised of the Platinum ® NGPS instrument, the Platinum Analysis Software service, reagent kits and semiconductor chips for use with its instruments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). All intercompany transactions are eliminated. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Condensed Consolidated Balance Sheet as of December 31, 2023 included herein was derived from the audited Consolidated Financial Statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP, on an annual reporting basis. In the opinion of management, the accompanying Condensed Consolidated Financial Statements reflect all normal recurring adjustments necessary to fairly state the financial position, results of operations, and cash flows for the interim periods. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2024, or any other period. There have been no material changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Global Developments Throughout 2023 , various central banks around the world, including the Federal Reserve in the United States, raised interest rates. While these rate increases have not had a significant adverse impact on the Company to date, the impact of such rate increases on the overall financial markets and the economy may adversely impact the Company in the future. In addition, the global economy has experienced, and is continuing to experience, high levels of inflation and global supply chain disruptions. The Company continues to monitor these supply chain, inflation and interest rate factors, as well as the uncertainty resulting from the overall economic environment. Although the Company does not expect to be significantly impacted by the ongoing conflicts in Ukraine or Israel and Gaza, the Company has experienced some constraints in product and material availability and increasing costs required to obtain some materials and supplies as a result of these conflicts on the global economy. To date, the Company’s business has not been materially impacted by the conflicts, however, as the conflicts continue or worsen, it may adversely impact the Company’s business, financial condition, results of operations and/or cash flows. Concentration of Business Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and marketable securities. As of September 30, 2024 and December 31, 2023, the Company’s marketable securities consist of money market mutual funds, U.S. Treasury securities and commercial paper. Th e Company also maintains balances in certain operating accounts above federally insured limits and, as a result, the Company is exposed to credit risk in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company sources certain key materials and components utilized in the Company’s products from single or limited suppliers. Historically, the Company has not experienced significant issues sourcing these materials and components. However, if these suppliers were not able to supply the requested amount of materials or components, it could take a considerable length of time to obtain alternative sources, which could affect the Company’s development efforts and commercial operations. Segment Reporting The Company’s Chief Operating Decision Maker, its Chief Executive Officer, reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates as a single reportable segment. Reclassifications Certain prior year amounts have been reclassified for consistency with the current year’s presentation. Use of Estimates The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that may affect the amounts recorded in its Condensed Consolidated Financial Statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions include: • valuation allowances with respect to deferred tax assets; • inventory valuation; • assumptions used for leases; • valuation of warrant liabilities; • assumptions associated with revenue recognition; and • assumptions underlying the fair value used in the calculation of stock-based compensation. The Company bases these estimates on historical and anticipated results and trends and on various other assumptions the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Condensed Consolidated Financial Statements. Inventory Inventory is stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Materials that may be utilized for either commercial or, alternatively, for research and development purposes, are classified as inventory. Amounts in inventory used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an “alternative future use” as defined in authoritative guidance. Inventory valuation is established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation, together with the calculation of the amount of such adjustments may require judgment. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, records a write-down of inventory to its estimated net realizable value in the period it is identified. For further discussion related to inventory, please refer to Note 5. Inventory . Warrant Liabilities The Company’s outstanding warrants include publicly traded warrants (the “Public Warrants”) and warrants sold in a private placement (the “Private Warrants”). The Public Warrants and Private Warrants meet the definition of a derivative, and the Company recorded these warrants as long-term liabilities in the Condensed Consolidated Balance Sheets at fair value upon initial recognition, with subsequent changes in their respective fair values recognized in the Condensed Consolidated Statements of Operations and Comprehensive Loss at each reporting date. For further discussion related to the Public Warrants and Private Warrants, please refer to Note 11. Warrant Liabilities . Revenue Recognition The Company’s revenue is derived from sales of products and services. Product revenue is primarily generated from the sales of instruments and consumables used in protein sequencing and analysis. Service revenue is primarily generated from service maintenance contracts including access to analysis software and advanced training for instrument use. The Company recognizes revenue when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue as the performance obligations have been satisfied. The Company has made the accounting policy election allowed for under ASC 606-10-32-2A to exclude all sales taxes from transaction price. Revenue recognition for contracts with multiple deliverables is based on the separate satisfaction of each distinct performance obligation within the contract. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company allocates the transaction price to the performance obligations in a contract with a customer based on the relative standalone selling price of each performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information and specific factors such as competitive positioning, internal costs, profit objectives, and internally approved pricing guidelines related to the performance obligation. The Company considers the performance obligation for sales of products satisfied upon shipment of the goods to the customer in accordance with the shipping terms (either upon shipment or delivery), which is when control of the product is deemed to be transferred; this includes instruments and consumables. Customers generally do not have a right to return products, except for defective or damaged products during the warranty period or unless prior written consent is provided. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenues for service maintenance contracts, which start after the first year of purchase and are considered as service type warranties that effectively extend the standard first-year service coverage at the customer’s option, are recognized ratably over the contract service period as these services are performed evenly over time. Revenues for advanced training is recognized at a point in time upon satisfaction of the underlying performance obligation. The Company typically provides a standard one-year warranty, which covers defects in materials, workmanship and manufacturing or performance conditions under normal use and service. The first year of the warranty of the products is considered an assurance-type warranty and is recorded as Cost of revenue within the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has determined the standard first-year warranty is not a distinct performance obligation. The Company disaggregates revenue from contracts with customers by type of revenue. The Company believes product revenue and service revenue aggregate the customer types by nature, amount, timing and uncertainty of its revenue streams. Total revenue generated from domestic sales was $0.4 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.8 million and $0.6 million for the nine months ended September 30, 2024 and 2023, respectively. Total revenue generated from international sales was $0.4 million and immaterial for the three months ended September 30, 2024 and 2023, respectively, and $1.1 million and $0.1 million for the nine months ended September 30, 2024 and 2023, respectively. Deferred Revenue Deferred revenue is a contract liability that consists of customer payments received in advance of performance or billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Deferred revenue primarily consists of billings and payments received in advance of revenue recognition from service maintenance contracts including software subscription and advanced training and is reduced as the revenue recognition criteria are met. Deferred revenue that will be recognized as revenue within the succeeding 12-month period is recorded as current and is included within Accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets. The portion of deferred revenue where revenue is expected to be recognized beyond 12 months from the reporting date is recorded as non-current deferred revenue and is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets. As of both September 30, 2024 and December 31, 2023, the Company recorded $0.1 million of deferred revenue within Accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets. As of both September 30, 2024 and December 31, 2023, amounts recorded within Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets were immaterial. The Company expects to recognize approximately 38% of its remaining performance obligations as revenue for the remainder of the year ending December 31, 2024. Stock-Based Compensation Stock-based compensation expense for stock option grants with only service conditions is recognized on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Stock-based compensation expense for stock option grants subject to performance conditions is recognized on an accelerated basis is recognized as though each vesting portion of the award was, in substance, a separate award. After the completion of the Business Combination, the Company measures compensation expense for stock-based awards to employees, non-employees and directors based upon the awards’ initial grant-date fair values. Stock-based compensation expense for stock options, restricted stock units and performance-based stock awards is recorded over the requisite service period. For awards with only a service condition, the Company expenses stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, the Company expenses the grant date fair value at the target over the vesting period regardless of the value the award recipients ultimately receive. The fair value of restricted stock unit awards without a market condition is estimated using the current market price of the Company’s Class A common stock on the date of grant. The fair value of stock option grants with a market condition is estimated at the date of grant using the Monte Carlo simulation model (“Monte Carlo”). The fair values of stock option grants with a service condition are estimated as of the date of grant by applying the Black-Scholes option valuation model (“Black-Scholes”). The Monte Carlo and Black-Scholes models incorporate assumptions as to stock price volatility, the expected life of the underlying stock options, a risk-free interest rate and dividend yield. The effect of forfeiture in compensation costs is recognized based on actual forfeitures when they occur. Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of Class A common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value. • Expected Term : The expected term using the “simplified” method, which is the simple average of the vesting period and the contractual term. • Risk-free Interest Rate : The risk-free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. • Expected Stock Price Volatility : The Company determined expected annual equity volatility based on a weighted average of the historical volatility of its Class A common stock and that of a selected peer group of comparable companies as the Company does not have a sufficient historical trading history of its own Class A common stock. • Dividend Yield : Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumes no dividend yield in valuing the stock-based awards. • Exercise Price : The exercise price is taken directly from the grant notice issued to employees and nonemployees. Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses ( “ DISE ” ), which requires additional disclosure of the nature of expenses included in the income statement. The ASU requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The ASU is required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU 2024-03 may have on its Consolidated Financial Statements and disclosures. In March 2024, the FASB issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements, which contains amendments to the Codification that remove references to various Concepts Statements. The amendments in ASU 2024-02 are not intended to result in significant accounting changes for most entities. The amendments in this update are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU 2024-02 may have on its Consolidated Financial Statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in ASU 2023-09 also remove disclosures related to certain unrecognized tax benefits and deferred taxes. The amendments are effective for fiscal years beginning after December 31, 2024, with early adoption permitted. The amendments may be applied prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 may have on its Consolidated Financial Statements and disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses. In addition, the ASU clarified that single reportable segment entities must apply Topic 280 in its entirely. The ASU does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The ASU is required to be applied retrospectively to all periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 may have on its financial position and results of operations upon adoption but does not expect the adoption will have a material impact on the Company ’ s Consolidated Financial Statements and disclosures.

Investments in Marketable Secur

Investments in Marketable Securities	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investments in Marketable Securities	Investments in Marketable Securities As of September 30, 2024 and December 31, 2023, the Company’s investments in marketable securities were determined to be available-for-sale securities. Dividend and interest income from marketable securities related to the Company’s available-for-sale securities for the three and nine months ended September 30, 2024 and dividend income from marketable securities, unrealized gain and realized loss on trading securities for the three and nine months ended September 30, 2023 were as follows (in thousands): Three months ended Nine months ended 2024 2023 2024 2023 Dividend income from marketable securities $ 233 $ 2,572 $ 1,576 $ 7,274 Interest income from marketable securities $ 2,455 $ — $ 7,573 $ — Unrealized gain on trading securities $ — $ 1,953 $ — $ 8,302 Realized loss on trading securities $ — $ (1,901) $ — $ (6,489) The following is a summary of the Company’s available-for-sale securities recorded within Marketable securities in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (in thousands): September 30, 2024 Amortized Gross Gross Fair Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 118,940 $ — $ 109 $ 119,049 Commercial paper 34,974 — 53 35,027 Total $ 153,914 $ — $ 162 $ 154,076 December 31, 2023 Amortized Gross Gross Fair Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 82,625 $ 15 $ — $ 82,640 Commercial paper 41,229 7 — 41,236 Total $ 123,854 $ 22 $ — $ 123,876 The fair values of the Company’s available-for-sale securities included within Marketable securities in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023, by remaining contractual maturity, are as follows (in thousands): September 30, 2024 One Year Over Over Total Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 119,049 $ — $ — $ 119,049 Commercial paper 35,027 — — 35,027 Total $ 154,076 $ — $ — $ 154,076 December 31, 2023 One Year Over Over Total Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 82,640 $ — $ — $ 82,640 Commercial paper 41,236 — — 41,236 Total $ 123,876 $ — $ — $ 123,876

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value. The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: • Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. • Level 2: Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. • Level 3: Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying value of cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates their fair values due to the short-term or on demand nature of these instruments. At September 30, 2024 and December 31, 2023 , the Company’s investment portfolio included available-for-sale securities which were comprised of money market funds, U.S. treasury bills and commercial paper. The Company has U.S. Treasury bills and commercial papers that are classified as Level 2 due to the fair value for these instruments being determined by utilizing observable inputs in similar assets or identical assets in non-active markets. The fair value of certain of the U.S. Treasury bills transferred to Level 2 from Level 1 of the fair value hierarchy due to trading activity, observability and accessibility of the pricing information from the most active market of the investment. Warrants are recorded as Warrant liabilities in the Condensed Consolidated Balance Sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented as Change in fair value of warrant liabilities in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Public Warrants and Private Warrants were carried at fair value as of September 30, 2024 and December 31, 2023 . The Public Warrants were valued using Level 1 inputs as they are traded in an active market. The Private Warrants were valued using a binomial lattice model. The primary unobservable input utilized in determining the fair value of the Private Warrants was the expected volatility of the Company’s Class A common stock. The expected volatility was based on consideration of the implied volatility from the Company’s own Public Warrant pricing and on the historical volatility observed at guideline public companies. As of September 30, 2024 , the significant assumptions used in preparing the binomial lattice model for valuing the Private Warrants liability include (i) volatility of 121.2%, (ii) risk-free interest rate of 3.7%, (iii) strike price of $11.50, (iv) fair value of Class A common stock of $0.88, and (v) expected life of 1.7 years. As of December 31, 2023 , the significant assumptions used in preparing the binomial lattice model for valuing the Private Warrants liability include (i) volatility of 92.1%, (ii) risk-free interest rate of 4.10%, (iii) strike price of $11.50, (iv) fair value of Class A common stock of $2.01, and (v) expected life of 2.4 years. There were no exercises or redemptions of the Public Warrants or Private Warrants during the three and nine months ended September 30, 2024 and 2023 . The following table summarizes the Company’s assets and liabilities in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023, that are measured at fair value on a recurring basis, by level, within the fair value hierarchy (in thousands): September 30, 2024 Level 1 Level 2 Level 3 Total Financial Assets: Cash equivalents: Money market funds $ 14,265 $ — $ — $ 14,265 Commercial paper 24,126 — — 24,126 Marketable securities: U.S. Treasury securities — 119,049 — 119,049 Commercial paper — 35,027 — 35,027 Total assets at fair value on a recurring basis $ 38,391 $ 154,076 $ — $ 192,467 Liabilities: Public Warrants $ 345 $ — $ — $ 345 Private Warrants — — 12 12 Total liabilities at fair value on a recurring basis $ 345 $ — $ 12 $ 357 December 31, 2023 Level 1 Level 2 Level 3 Total Financial Assets: Cash equivalents: Money market funds $ 50,226 $ — $ — $ 50,226 U.S. Treasury securities 59,654 — — 59,654 Commercial paper — 19,436 — 19,436 Marketable securities: U.S. Treasury securities 82,640 — — 82,640 Commercial paper — 41,236 — 41,236 Total assets at fair value on a recurring basis $ 192,520 $ 60,672 $ — $ 253,192 Liabilities: Public Warrants $ 1,227 $ — $ — $ 1,227 Private Warrants — — 47 47 Total liabilities at fair value on a recurring basis $ 1,227 $ — $ 47 $ 1,274

Inventory

Inventory	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following as of September 30, 2024 and December 31, 2023 (in thousands): September 30, December 31, Raw materials $ 1,666 $ 1,608 Work in progress 1,433 779 Finished goods 992 1,558 Total inventory $ 4,091 $ 3,945 For the three and nine months ended September 30, 2024, the Company recorded charges for inventory write-downs of $0.8 million and $2.4 million, respectively, in Research and Development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. There were no charges for inventory write-downs during the three and nine months ended September 30, 2023.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net, consists of the following as of September 30, 2024 and December 31, 2023 (in thousands): September 30, December 31, Laboratory and production equipment $ 16,491 $ 14,727 Computer equipment 1,733 1,707 Purchased software 188 188 Furniture and fixtures 325 310 Leasehold improvements 7,226 6,948 Construction in process 3,698 2,438 Subtotal 29,661 26,318 Less: Accumulated depreciation and amortization (13,407) (10,043) Property and equipment, net $ 16,254 $ 16,275 Depreciation and amortization expense is included within Cost of revenue and Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Leases Lease-related costs for the three and nine months ended September 30, 2024 and 2023 are as follows (in thousands): Three months ended Nine months ended 2024 2023 2024 2023 Operating lease cost $ 865 $ 864 $ 2,593 $ 2,613 Variable lease cost 497 545 1,325 1,226 Total lease cost $ 1,362 $ 1,409 $ 3,918 $ 3,839 Future minimum lease payments under non-cancellable leases as of September 30, 2024 are as follows (dollars in thousands): Remaining Lease Payments Remainder of 2024 $ 1,127 2025 4,527 2026 4,585 2027 4,549 2028 2,975 Thereafter 10,052 Total remaining undiscounted lease payments $ 27,815 Less: Imputed interest (4,886) Less: Lease incentives (1) (9,104) Total lease liabilities 13,825 Less: current portion (3,614) Long-term operating lease liabilities $ 10,211 Weighted-average remaining lease term (in years) 5.8 Weighted-average discount rate 7.9 % (1) Includes lease incentives that are estimated to be realized in 2026 and 2027 for the costs of leasehold improvements. The following table provides certain cash flow and supplemental cash flow information related to the Company’s right-of-use assets and lease liabilities for the nine months ended September 30, 2024 and 2023 (in thousands): Nine months ended September 30, 2024 2023 Operating cash paid to settle operating lease liabilities $ 3,310 $ 3,201 Right-of-use assets obtained in exchange for lease liabilities (2) $ 1,047 $ 83 (2) The nine months ended September 30, 2024 includes an increase in right-of-use assets due to the change in estimated timing of receipt of reimbursements for tenant improvements. In December 2021, the Company signed a 10-year lease for approximately 67,000 square feet of space in New Haven, Connecticut. The lease commenced on January 8, 2022 with rent payments beginning on July 7, 2022. Under the lease, the landlord contractually agreed to reimburse the Company for up to $9.1 million in improvements to the space, to be used for such improvements as the Company deems “necessary or desirable”. On September 13, 2022, the Company filed a lawsuit against the landlord, alleging that the landlord has: (i) refused to reimburse the Company for costs related to improvements already incurred and submitted, (ii) delayed the Company’s completion of improvements, in order to avoid reimbursing the costs of those improvements, and (iii) improperly rejected the Company’s proposed improvement plans. The Company accounted for these lease incentives as an offset to the lease liability recorded at the inception of the lease. In September 2024, the Company determined there was a change in the estimated timing of receipt of reimbursements for the improvements. This resulted in an increase of the carrying value of the right-of-use asset and the corresponding lease liabilities of $1.0 million. Although the Company believes it is contractually entitled to the $9.1 million of lease incentives, based on the current status of the litigation, the Company cannot determine the likely outcome or estimate the impact on such carrying values.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, Restructuring costs $ — $ 519 Severance costs 206 — Legal fees 1,008 979 Royalties 110 123 Other 1,515 194 Total accrued expenses and other current liabilities $ 2,839 $ 1,815

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plan The Quantum-Si Incorporated 2021 Equity Incentive Plan (the “2021 Plan”) provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing consulting or advisory services for the Company, are eligible for grants under the 2021 Plan. As of September 30, 2024 , there were 13,204,915 shares available for future grant under the 2021 Plan. Inducement Equity Incentive Plan On May 8, 2023 , the Company adopted the 2023 Inducement Equity Incentive Plan (the “2023 Inducement Plan”) to reserve 3,000,000 shares of its Class A common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. On August 23, 2024 , the Company amended the 2023 Inducement Plan to reserve an additional 3,000,000 shares of its Class A common stock under the 2023 Inducement Plan. As of September 30, 2024 , there were 2,268,867 shares available for future issuance under the 2023 Inducement Plan, as amended. The terms and conditions of the 2023 Inducement Plan, as amended, are substantially similar to those of the 2021 Plan. Stock Options The Company recorded $1.7 million and $1.1 million for stock-based compensation related to stock options for the three months ended September 30, 2024 and 2023, respectively, and $4.8 million and $5.7 million for stock-based compensation related to stock options for the nine months ended September 30, 2024 and 2023, respectively. The Company estimates and records the compensation cost associated with the grants described above with an offsetting entry to paid-in capital. The Company utilized the Black-Scholes option pricing model for determining the estimated fair value for service or performance-based stock awards where performance is not tied to market conditions. The Black-Scholes option pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. The fair value of each stock option award granted during the nine months ended September 30, 2024 was estimated as of the grant date using a Black-Scholes model with the following assumptions: Nine months ended Expected term (in years) 4.6 - 5.0 Risk-free interest rate 3.4% - 5.2% Expected volatility 82.4% - 90.6% Expected dividend yield — Weighted average grant date fair value per share $1.03 A summary of the stock option activity for the nine months ended September 30, 2024 is presented in the table below: Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2023 22,511,900 $ 2.79 8.2 $ 3,194 Granted 2,282,600 1.51 Exercised (137,539) 1.00 Forfeited (2,385,526) 3.06 Expired (115,262) 2.45 Outstanding at September 30, 2024 22,156,173 $ 2.64 8.0 $ 51 Options exercisable at September 30, 2024 9,292,622 $ 3.27 6.8 $ 51 Vested and expected to vest at September 30, 2024 19,025,789 $ 2.72 7.8 $ 51 Modification of Performance Stock Options In November 2022 and May 2023, the Company granted 2,780,000 and 1,000,000 performance-based stock option awards to its Chief Executive Officer and Chief Financial Officer, respectively. The vesting of these awards are subject to continued service to the Company and certain market conditions. The market conditions require the Company’s Class A common stock trade above specified levels for certain periods of time. The fair values of the awards were estimated at the grant date using the Monte Carlo simulation model. On March 15, 2024, the market conditions that trigger the vesting of these performance-based stock option awards were modified. The modified market conditions require the Company’s Class A common stock to trade above specified levels for certain defined periods of time that are different from the original awards. The Company accounted for the modifications as modifications of market conditions. The total incremental stock-based compensation expense to be recognized for these awards is approximately $2.4 million within Selling, general and administrative operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Incremental stock-based compensation expense for the three and nine months ended September 30, 2024 was $0.2 million and $0.4 million, respectively. There were no such modifications to performance-based stock option awards for the three and nine months ended September 30, 2023. Restricted Stock Units The Company recorded $0.7 million of stock-based compensation expense related to restricted stock unit (“RSU”) awards for the three months ended September 30, 2024. Stock-based compensation expense related to RSU awards for the three months ended September 30, 2023 was immaterial. The Company recorded $1.7 million and $1.2 million of s tock-based compensation expense related to RSU awards for the nine months ended September 30, 2024 and 2023, respectively. The nine months ended September 30, 2023 included a reversal of stock-based compensation expense for the Company’s former Chief Financial Officer and certain members of the Company’s board of directors (the “Board”) as the service conditions of certain awards previously granted were not met. A summary of the RSU activity for the nine months ended September 30, 2024 is presented in the table below: Number Weighted Average Grant-Date Fair Value Outstanding non-vested RSUs at December 31, 2023 847,169 $ 2.68 Granted 8,380,356 1.51 Vested (805,396) 2.55 Forfeited (972,207) 1.74 Outstanding non-vested RSUs at September 30, 2024 7,449,922 $ 1.51 The Company’s stock-based compensation is allocated to the following operating expense categories as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Research and development $ 754 $ 479 $ 2,012 $ 2,531 Selling, general and administrative 1,657 662 4,470 4,383 Total stock-based compensation $ 2,411 $ 1,141 $ 6,482 $ 6,914

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The Company presents both basic earnings per share (“EPS”) and diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all common share equivalents to the extent they are dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common share equivalents would have been anti-dilutive. The following table presents the calculations for the three and nine months ended September 30, 2024 and 2023 of basic and diluted net loss per share for the Company’s common stock (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Numerator Net loss $ (25,313) $ (24,728) $ (67,886) $ (73,912) Numerator for basic and diluted EPS - loss attributable to common stockholders $ (25,313) $ (24,728) $ (67,886) $ (73,912) Denominator Common stock 142,399 141,660 142,039 141,154 Denominator for basic and diluted EPS - weighted-average common stock 142,399 141,660 142,039 141,154 Basic and diluted net loss per share $ (0.18) $ (0.17) $ (0.48) $ (0.52) Net loss per share attributable to Class A and Class B common stockholders was the same on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive. The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive for the three and nine months ended September 30, 2024 and 2023 (in thousands) : September 30, 2024 2023 Outstanding options to purchase common stock 22,156,173 23,621,828 Outstanding restricted stock units 7,449,922 640,674 Outstanding warrants 3,968,319 3,968,319 33,574,414 28,230,821

Warrant Liabilities

Warrant Liabilities	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrant Liabilities	Warrant Liabilities Public Warrants As of September 30, 2024 and December 31, 2023 , there were an aggregate of 3,833,319 outstanding Public Warrants, which entitle the holder to acquire Class A common stock. Each whole warrant entitles the registered holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment as discussed below, beginning on September 9, 2021. The warrants will expire on June 10, 2026 or earlier upon redemption or liquidation. Redemptions At any time while the warrants are exercisable, the Company may redeem not less than all of the outstanding Public Warrants: • in whole and not in part; • at a price of $0.01 per warrant; • upon not less than 30 days ’ prior written notice of redemption (the “ 30 -day redemption period”) to each warrant holder; and • if, and only if, the closing price of the Company’s Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 -trading day period ending three business days before the Company sends the notice of redemption to the warrant holders. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the Public Warrants at $0.01 per warrant, each holder of Public Warrants will be entitled to exercise their Public Warrants held prior to the scheduled redemption date. If the Company calls the Public Warrants for redemption for $0.01 as described above, the Board may elect to require any holder that wishes to exercise his, her or its Public Warrants to do so on a “cashless basis.” If the Board makes such election, all holders of Public Warrants would pay the exercise price by surrendering their warrants for that number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the warrants, multiplied by the excess of the “fair market value” over the exercise price of the warrants by (y) the “fair market value”. For purposes of the redemption provisions of the warrants, the “fair market value” means the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. The Public Warrants do not meet the criteria to be classified in stockholders’ equity as the exercise of the Public Warrants may be settled in cash upon the occurrence of a tender offer or exchange offer in which the maker of the tender offer or exchange offer, upon completion of the tender offer or exchange offer, beneficially owns more than 50% of the outstanding shares of the Company’s Class A common stock, even if it would not result in a change of control of the Company. This provision precludes the Public Warrants from being classified in equity and thus they are classified as long-term liabilities in the Condensed Consolidated Balance Sheets. Private Warrants As of September 30, 2024 and December 31, 2023 , there were 135,000 Private Warrants outstanding. The Private Warrants are identical to the Public Warrants, except that so long as they are held by HighCape Capital Acquisition LLC or any of its permitted transferees, (i) the Private Warrants and the shares of Class A common stock issuable upon the exercise of the Private Warrants were not transferable, assignable or saleable until 30 days after the completion of the Business Combination, (ii) the Private Warrants will be exercisable for cash or on a cashless basis, at the holder’s option, and (iii) the Private Warrants are not subject to the Company’s redemption option at the price of $0.01 per warrant. The Private Warrants are subject to the Company’s redemption option at the price of $0.01 per warrant, provided that the other conditions of such redemption are met, as described above. If the Private Warrants are held by a holder other than HighCape Capital Acquisition LLC or any of its permitted transferees, the Private Warrants will be redeemable by the Company in all redemption scenarios applicable to the Public Warrants and exercisable by such holders on the same basis as the Public Warrants. The Private Warrants do not meet the criteria to be classified in stockholders’ equity as the terms of the warrants provide for potential changes to the settlement amounts depending upon the characteristics of the warrant holder, and, because the holder of a warrant is not an input into the pricing of a fixed-for-fixed option on equity shares. This provision precludes the Private Warrants from being classified in equity and thus they are classified as long-term liabilities in the Condensed Consolidated Balance Sheets. The fair value of warrant liabilities was $0.4 million and $1.3 million as of September 30, 2024 and December 31, 2023, respectively. The Company recognized a gain of $0.1 million and a loss of $0.2 million as a Change in fair value of warrant liabilities in the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended September 30, 2024 and 2023, respectively. The Company recognized a gain of $0.9 million and a loss of $0.1 million as a Change in fair value of warrant liabilities in the Condensed Consolidated Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2024 and 2023, respectively. There were no exercises or redemptions of the Public Warrants or Private Warrants during the three and nine months ended September 30, 2024 or 2023 .

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring The Company committed to organizational restructurings during the first and third quarters of 2023, designed to decrease its costs and create a more streamlined organization to support its business. As of December 31, 2023, the Company recorded a restructuring liability of $0.5 million which is included in Accrued expenses and other current liabilities in the Condensed Consolidated Balance Sheets. As of September 30, 2024, the Company had no remaining restructuring liability. The Company’s restructuring costs, primarily for cash severance and other severance costs, are allocated to the following operating expense categories as follows (in thousands): Research and development Selling, general and administrative Total Balance as of December 31, 2023 $ 513 $ 6 $ 519 Restructuring charges incurred (1) 131 — 131 Cash payments and other adjustments (1) (422) (6) (428) Balance as of March 31, 2024 222 — 222 Cash payments and other adjustments (1) (216) — (216) Balance as of June 30, 2024 6 — 6 Cash payments and other adjustments (1) (6) — (6) Balance as of September 30, 2024 $ — $ — $ — Current liabilities $ — Long-term liabilities — Total liabilities as of September 30, 2024 $ — (1) Restructuring charges incurred and Cash payments and other adjustments include non-cash charges related to stock-based compensation expenses. The Company’s restructuring activities were complete as of March 31, 2024. The Company does not expect to incur additional charges associated with these activities.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes for the three and nine months ended September 30, 2024 and 2023 were recorded at the Company’s estimated annual effective income tax rate, subject to adjustments for discrete events, if they occur. The Company’s estimated annual effective tax rate for the three and nine months ended September 30, 2024 was (0.17)% and (0.06)%, respectively. The Company’s estimated annual effective tax rate for each of the three and nine months ended September 30, 2023 was 0.0% . The primary reconciling items between the federal statutory rate of 21.0% and the Company’s overall effective tax rate for these periods were related to stock-based compensation, the valuation allowance recorded against the full amount of the Company’s net deferred tax assets and foreign taxes. A valuation allowance is required when it is more likely than not that some portion or all of the Company’s deferred tax assets will not be realized. The realization of deferred tax assets depends on the generation of sufficient future taxable income during the period in which the Company’s related temporary differences become deductible. Management believes that based on the earnings history of the Company, it is more likely than not that the benefits of these assets will not be realized, and therefore, a full valuation allowance has been recorded against the Company’s net deferred tax assets as of September 30, 2024 and December 31, 2023 .

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Effective as of February 17, 2021, legacy Quantum-Si entered into a Master Services Agreement (“MSA”) with 4Catalyzer Corporation (“4C”), a company controlled by Dr. Jonathan Rothberg, a member of the Board, pursuant to which the Company may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided. The Company incurred expenses payable to 4C of $0.1 million for both the three m onths ended September 30, 2024 and 2023, and $0.2 million and $0.3 million for the nine m onths ended September 30, 2024 and 2023, respectively. These expenses included amounts for month-to-month sublease arrangements for office and laboratory spaces from 4C and certain administrative expenses. These amounts are included in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Effective October 1, 2022, the Company entered into a Protein Engineering Collaboration (the “New Collaboration”) with Protein Evolution, Inc. (“PEI”) to develop technology and methods in the field of nanobodies and potentially other binders to produce novel biological reagents and related data. Dr. Rothberg serves as a member of the board of directors of PEI and the Rothberg family are controlling stockholders of PEI. As of September 30, 2024 there was no amount due from PEI to the Company related to the New Collaboration . As of December 31, 2023, the amount due from PEI to the Company related to the New Collaboration was $0.3 million. The New Collaboration was terminated effective May 1, 2024. Effective November 1, 2022, the Company entered into an Advisory Agreement with Dr. Rothberg (the “Advisory Agreement”), pursuant to which Dr. Rothberg serves as a member of the Board, advises the Chief Executive Officer and the Board on strategic matters, and provides consulting, business development and similar services on matters relating to the Company’s current, future and potential scientific and strategic initiatives and such other consulting services reasonably requested from time to time. Pursuant to the Advisory Agreement, as compensation for the services provided thereunder, in March 2023 , the Company granted Dr. Rothberg an option to purchase 250,000 shares of Class A common stock pursuant to the 2021 Plan.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Licenses related to certain intellectual property: The Company licenses certain intellectual property, some of which may be utilized in its current or future product offerings. To preserve the right to use such intellectual property, the Company is required to make annual minimum fixed payments totaling approximately $0.1 million as well as royalties based on net sales if the royalties exceed annual minimum fixed payments. As of September 30, 2024 and December 31, 2023, the Company had accrued royalties of approximately $0.1 million included in Accrued expenses and other current liabilities in the Condensed Consolidated Balance Sheets. Other commitments: The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees (the “401(k) Plan”). Contributions to the 401(k) Plan are discretionary. The Company did not make any matching contributions to the 401(k) Plan for the three and nine months ended September 30, 2024 and 2023 . Contingencies The Company is subject to claims in the ordinary course of business. The Company accrues contingent liabilities to the extent the liability is probable and estimable. On May 16, 2024, a punitive class action lawsuit was filed in the Delaware Court of Chancery, styled Farzad v. HighCape Capital, et al. (the “Delaware Stockholder Litigation”). The Delaware Stockholder Litigation asserts breach of fiduciary duty claims against the former officers and directors of HighCape, including Kevin Rakin, Matt Zuga, David Colpman, Robert Taub and Antony Loebel, HighCape Capital Acquisition LLC and HighCape Capital L.P., aiding and abetting breach of fiduciary duty claims against Foresite Capital Management, LLC and Dr. Rothberg, and unjust enrichment claims against all defendants related to the Business Combination. The Delaware Stockholder Litigation complaint alleges that the transactions contemplated by the Business Combination were a product of an unfair process which was allegedly impacted by conflicts of interest, resulting in mispricing of the Business Combination. The complaint seeks, among other things, unspecified damages and attorneys’ fees and costs. On July 29, 2024, the defendants filed motions to dismiss the Delaware Stockholder Litigation complaint. There is no assurance that defendants will be successful in the defense of the litigation or that insurance will be available or adequate to fund any potential settlement or judgment or the litigation costs of the action. At the time of this filing the outcome of this matter is not estimable or probable. In April 2023, the Company informed the contract manufacturer that had manufactured its Platinum ® and Carbon™ instruments that it intended to wind down the relationship and transition to a different contract manufacturer. In October 2023, the former contract manufacturer filed a complaint against the Company in the State of Texas alleging breach of contract and made claims for economic damage and attorney costs. In January 2024, the suit was withdrawn and refiled in the State of Minnesota alleging similar claims. Although it is not possible to determine the potential financial exposure associated with the alleged claim at this time given its early stage, the Company believes it has a meritorious defense and intends to vigorously defend against all claims asserted in the complaint. At the time of this filing the outcome of this matter is not estimable or probable. The Company enters into agreements that contain indemnification provisions with other parties in the ordinary course of business, including business partners, investors, contractors, and the Company’s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or threatened third-party claims because of the Company’s activities or non-compliance with certain representations and warranties made by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss in connection with the indemnification provisions have not been material.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event Nasdaq Deficiency Notice On November 4, 2024, the Company received a notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s Class A common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). While the Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on The Nasdaq Global Select Market, the Company has until May 5, 2025 to regain compliance. If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (25,313)	$ (23,099)	$ (19,474)	$ (24,728)	$ (25,573)	$ (23,611)	$ (67,886)	$ (73,912)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Jonathan M. Rothberg [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Effective September 13, 2024, in connection with estate planning, entities owned by trusts created for the benefit of Dr. Rothberg’s children, who is a member of the Board, entered into a 10b5-1 sales plan (the “Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Sales Plan provides for the sale of up to 6,250,000 shares of the Company’s Class A common stock beginning on January 13, 2025 and shall terminate upon the earliest of (i) January 13, 2026, (ii) the sale of 6,250,000 shares of the Company’s Class A common stock, or (iii) the occurrence of any of the other terminating events set forth in the Sales Plan.
Name	Dr. Rothberg’s children
Title	member of the Board
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 13, 2024
Expiration Date	January 13, 2026
Arrangement Duration	365 days
Aggregate Available	6,250,000	6,250,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). All intercompany transactions are eliminated. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Condensed Consolidated Balance Sheet as of December 31, 2023 included herein was derived from the audited Consolidated Financial Statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP, on an annual reporting basis. In the opinion of management, the accompanying Condensed Consolidated Financial Statements reflect all normal recurring adjustments necessary to fairly state the financial position, results of operations, and cash flows for the interim periods. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2024, or any other period. There have been no material changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Business Risk	Concentration of Business Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and marketable securities. As of September 30, 2024 and December 31, 2023, the Company’s marketable securities consist of money market mutual funds, U.S. Treasury securities and commercial paper. Th e Company also maintains balances in certain operating accounts above federally insured limits and, as a result, the Company is exposed to credit risk in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company sources certain key materials and components utilized in the Company’s products from single or limited suppliers. Historically, the Company has not experienced significant issues sourcing these materials and components. However, if these suppliers were not able to supply the requested amount of materials or components, it could take a considerable length of time to obtain alternative sources, which could affect the Company’s development efforts and commercial operations.
Segment Reporting	Segment Reporting The Company’s Chief Operating Decision Maker, its Chief Executive Officer, reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates as a single reportable segment.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current year’s presentation.
Use of Estimates	Use of Estimates The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that may affect the amounts recorded in its Condensed Consolidated Financial Statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions include: • valuation allowances with respect to deferred tax assets; • inventory valuation; • assumptions used for leases; • valuation of warrant liabilities; • assumptions associated with revenue recognition; and • assumptions underlying the fair value used in the calculation of stock-based compensation. The Company bases these estimates on historical and anticipated results and trends and on various other assumptions the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Condensed Consolidated Financial Statements.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Materials that may be utilized for either commercial or, alternatively, for research and development purposes, are classified as inventory. Amounts in inventory used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an “alternative future use” as defined in authoritative guidance.
Warrant Liabilities	Warrant Liabilities
Revenue Recognition	Revenue Recognition The Company’s revenue is derived from sales of products and services. Product revenue is primarily generated from the sales of instruments and consumables used in protein sequencing and analysis. Service revenue is primarily generated from service maintenance contracts including access to analysis software and advanced training for instrument use. The Company recognizes revenue when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue as the performance obligations have been satisfied. The Company has made the accounting policy election allowed for under ASC 606-10-32-2A to exclude all sales taxes from transaction price. Revenue recognition for contracts with multiple deliverables is based on the separate satisfaction of each distinct performance obligation within the contract. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company allocates the transaction price to the performance obligations in a contract with a customer based on the relative standalone selling price of each performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information and specific factors such as competitive positioning, internal costs, profit objectives, and internally approved pricing guidelines related to the performance obligation. The Company considers the performance obligation for sales of products satisfied upon shipment of the goods to the customer in accordance with the shipping terms (either upon shipment or delivery), which is when control of the product is deemed to be transferred; this includes instruments and consumables. Customers generally do not have a right to return products, except for defective or damaged products during the warranty period or unless prior written consent is provided. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenues for service maintenance contracts, which start after the first year of purchase and are considered as service type warranties that effectively extend the standard first-year service coverage at the customer’s option, are recognized ratably over the contract service period as these services are performed evenly over time. Revenues for advanced training is recognized at a point in time upon satisfaction of the underlying performance obligation. The Company typically provides a standard one-year warranty, which covers defects in materials, workmanship and manufacturing or performance conditions under normal use and service. The first year of the warranty of the products is considered an assurance-type warranty and is recorded as Cost of revenue within the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has determined the standard first-year warranty is not a distinct performance obligation.
Deferred Revenue	Deferred Revenue Deferred revenue is a contract liability that consists of customer payments received in advance of performance or billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Deferred revenue primarily consists of billings and payments received in advance of revenue recognition from service maintenance contracts including software subscription and advanced training and is reduced as the revenue recognition criteria are met. Deferred revenue that will be recognized as revenue within the succeeding 12-month period is recorded as current and is included within Accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets. The portion of deferred revenue where revenue is expected to be recognized beyond 12 months from the reporting date is recorded as non-current deferred revenue and is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets. As of both September 30, 2024 and December 31, 2023, the Company recorded $0.1 million of deferred revenue within Accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets. As of both September 30, 2024 and December 31, 2023, amounts recorded within Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets were immaterial. The Company expects to recognize approximately 38% of its remaining performance obligations as revenue for the remainder of the year ending December 31, 2024.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense for stock option grants with only service conditions is recognized on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date fair values. Stock-based compensation expense for stock option grants subject to performance conditions is recognized on an accelerated basis is recognized as though each vesting portion of the award was, in substance, a separate award. After the completion of the Business Combination, the Company measures compensation expense for stock-based awards to employees, non-employees and directors based upon the awards’ initial grant-date fair values. Stock-based compensation expense for stock options, restricted stock units and performance-based stock awards is recorded over the requisite service period. For awards with only a service condition, the Company expenses stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, the Company expenses the grant date fair value at the target over the vesting period regardless of the value the award recipients ultimately receive. The fair value of restricted stock unit awards without a market condition is estimated using the current market price of the Company’s Class A common stock on the date of grant. The fair value of stock option grants with a market condition is estimated at the date of grant using the Monte Carlo simulation model (“Monte Carlo”). The fair values of stock option grants with a service condition are estimated as of the date of grant by applying the Black-Scholes option valuation model (“Black-Scholes”). The Monte Carlo and Black-Scholes models incorporate assumptions as to stock price volatility, the expected life of the underlying stock options, a risk-free interest rate and dividend yield. The effect of forfeiture in compensation costs is recognized based on actual forfeitures when they occur. Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of Class A common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value. • Expected Term : The expected term using the “simplified” method, which is the simple average of the vesting period and the contractual term. • Risk-free Interest Rate : The risk-free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. • Expected Stock Price Volatility : The Company determined expected annual equity volatility based on a weighted average of the historical volatility of its Class A common stock and that of a selected peer group of comparable companies as the Company does not have a sufficient historical trading history of its own Class A common stock. • Dividend Yield : Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumes no dividend yield in valuing the stock-based awards. • Exercise Price : The exercise price is taken directly from the grant notice issued to employees and nonemployees.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses ( “ DISE ” ), which requires additional disclosure of the nature of expenses included in the income statement. The ASU requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The ASU is required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact ASU 2024-03 may have on its Consolidated Financial Statements and disclosures. In March 2024, the FASB issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements, which contains amendments to the Codification that remove references to various Concepts Statements. The amendments in ASU 2024-02 are not intended to result in significant accounting changes for most entities. The amendments in this update are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU 2024-02 may have on its Consolidated Financial Statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in ASU 2023-09 also remove disclosures related to certain unrecognized tax benefits and deferred taxes. The amendments are effective for fiscal years beginning after December 31, 2024, with early adoption permitted. The amendments may be applied prospectively or retrospectively. The Company is currently evaluating the impact ASU 2023-09 may have on its Consolidated Financial Statements and disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses. In addition, the ASU clarified that single reportable segment entities must apply Topic 280 in its entirely. The ASU does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The ASU is required to be applied retrospectively to all periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact ASU 2023-07 may have on its financial position and results of operations upon adoption but does not expect the adoption will have a material impact on the Company ’ s Consolidated Financial Statements and disclosures.

Investments in Marketable Sec_2

Investments in Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Unrealized and Realized Gains/(Losses) and Dividend Income on Marketable Securities	Dividend and interest income from marketable securities related to the Company’s available-for-sale securities for the three and nine months ended September 30, 2024 and dividend income from marketable securities, unrealized gain and realized loss on trading securities for the three and nine months ended September 30, 2023 were as follows (in thousands): Three months ended Nine months ended 2024 2023 2024 2023 Dividend income from marketable securities $ 233 $ 2,572 $ 1,576 $ 7,274 Interest income from marketable securities $ 2,455 $ — $ 7,573 $ — Unrealized gain on trading securities $ — $ 1,953 $ — $ 8,302 Realized loss on trading securities $ — $ (1,901) $ — $ (6,489)
Schedule of Available-for-Sale Securities Reconciliation	The following is a summary of the Company’s available-for-sale securities recorded within Marketable securities in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (in thousands): September 30, 2024 Amortized Gross Gross Fair Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 118,940 $ — $ 109 $ 119,049 Commercial paper 34,974 — 53 35,027 Total $ 153,914 $ — $ 162 $ 154,076 December 31, 2023 Amortized Gross Gross Fair Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 82,625 $ 15 $ — $ 82,640 Commercial paper 41,229 7 — 41,236 Total $ 123,854 $ 22 $ — $ 123,876
Investments Classified by Contractual Maturity Date	The fair values of the Company’s available-for-sale securities included within Marketable securities in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023, by remaining contractual maturity, are as follows (in thousands): September 30, 2024 One Year Over Over Total Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 119,049 $ — $ — $ 119,049 Commercial paper 35,027 — — 35,027 Total $ 154,076 $ — $ — $ 154,076 December 31, 2023 One Year Over Over Total Financial Assets: Short-term marketable securities: U.S. Treasury securities $ 82,640 $ — $ — $ 82,640 Commercial paper 41,236 — — 41,236 Total $ 123,876 $ — $ — $ 123,876

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes the Company’s assets and liabilities in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023, that are measured at fair value on a recurring basis, by level, within the fair value hierarchy (in thousands): September 30, 2024 Level 1 Level 2 Level 3 Total Financial Assets: Cash equivalents: Money market funds $ 14,265 $ — $ — $ 14,265 Commercial paper 24,126 — — 24,126 Marketable securities: U.S. Treasury securities — 119,049 — 119,049 Commercial paper — 35,027 — 35,027 Total assets at fair value on a recurring basis $ 38,391 $ 154,076 $ — $ 192,467 Liabilities: Public Warrants $ 345 $ — $ — $ 345 Private Warrants — — 12 12 Total liabilities at fair value on a recurring basis $ 345 $ — $ 12 $ 357 December 31, 2023 Level 1 Level 2 Level 3 Total Financial Assets: Cash equivalents: Money market funds $ 50,226 $ — $ — $ 50,226 U.S. Treasury securities 59,654 — — 59,654 Commercial paper — 19,436 — 19,436 Marketable securities: U.S. Treasury securities 82,640 — — 82,640 Commercial paper — 41,236 — 41,236 Total assets at fair value on a recurring basis $ 192,520 $ 60,672 $ — $ 253,192 Liabilities: Public Warrants $ 1,227 $ — $ — $ 1,227 Private Warrants — — 47 47 Total liabilities at fair value on a recurring basis $ 1,227 $ — $ 47 $ 1,274

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Net Inventory	Inventory consists of the following as of September 30, 2024 and December 31, 2023 (in thousands): September 30, December 31, Raw materials $ 1,666 $ 1,608 Work in progress 1,433 779 Finished goods 992 1,558 Total inventory $ 4,091 $ 3,945

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment, net, consists of the following as of September 30, 2024 and December 31, 2023 (in thousands): September 30, December 31, Laboratory and production equipment $ 16,491 $ 14,727 Computer equipment 1,733 1,707 Purchased software 188 188 Furniture and fixtures 325 310 Leasehold improvements 7,226 6,948 Construction in process 3,698 2,438 Subtotal 29,661 26,318 Less: Accumulated depreciation and amortization (13,407) (10,043) Property and equipment, net $ 16,254 $ 16,275

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Lease-Related Costs	Lease-related costs for the three and nine months ended September 30, 2024 and 2023 are as follows (in thousands): Three months ended Nine months ended 2024 2023 2024 2023 Operating lease cost $ 865 $ 864 $ 2,593 $ 2,613 Variable lease cost 497 545 1,325 1,226 Total lease cost $ 1,362 $ 1,409 $ 3,918 $ 3,839
Future Minimum Lease Payments Under Non-Cancellable Leases	Future minimum lease payments under non-cancellable leases as of September 30, 2024 are as follows (dollars in thousands): Remaining Lease Payments Remainder of 2024 $ 1,127 2025 4,527 2026 4,585 2027 4,549 2028 2,975 Thereafter 10,052 Total remaining undiscounted lease payments $ 27,815 Less: Imputed interest (4,886) Less: Lease incentives (1) (9,104) Total lease liabilities 13,825 Less: current portion (3,614) Long-term operating lease liabilities $ 10,211 Weighted-average remaining lease term (in years) 5.8 Weighted-average discount rate 7.9 % (1) Includes lease incentives that are estimated to be realized in 2026 and 2027 for the costs of leasehold improvements.
Supplemental Cash Flow Information Related to Operating Leases	The following table provides certain cash flow and supplemental cash flow information related to the Company’s right-of-use assets and lease liabilities for the nine months ended September 30, 2024 and 2023 (in thousands): Nine months ended September 30, 2024 2023 Operating cash paid to settle operating lease liabilities $ 3,310 $ 3,201 Right-of-use assets obtained in exchange for lease liabilities (2) $ 1,047 $ 83 (2) The nine months ended September 30, 2024 includes an increase in right-of-use assets due to the change in estimated timing of receipt of reimbursements for tenant improvements.

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, Restructuring costs $ — $ 519 Severance costs 206 — Legal fees 1,008 979 Royalties 110 123 Other 1,515 194 Total accrued expenses and other current liabilities $ 2,839 $ 1,815

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Fair Value Of Each Stock Option Award	The fair value of each stock option award granted during the nine months ended September 30, 2024 was estimated as of the grant date using a Black-Scholes model with the following assumptions: Nine months ended Expected term (in years) 4.6 - 5.0 Risk-free interest rate 3.4% - 5.2% Expected volatility 82.4% - 90.6% Expected dividend yield — Weighted average grant date fair value per share $1.03
Stock Option Activity	A summary of the stock option activity for the nine months ended September 30, 2024 is presented in the table below: Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2023 22,511,900 $ 2.79 8.2 $ 3,194 Granted 2,282,600 1.51 Exercised (137,539) 1.00 Forfeited (2,385,526) 3.06 Expired (115,262) 2.45 Outstanding at September 30, 2024 22,156,173 $ 2.64 8.0 $ 51 Options exercisable at September 30, 2024 9,292,622 $ 3.27 6.8 $ 51 Vested and expected to vest at September 30, 2024 19,025,789 $ 2.72 7.8 $ 51
RSU Activity	A summary of the RSU activity for the nine months ended September 30, 2024 is presented in the table below: Number Weighted Average Grant-Date Fair Value Outstanding non-vested RSUs at December 31, 2023 847,169 $ 2.68 Granted 8,380,356 1.51 Vested (805,396) 2.55 Forfeited (972,207) 1.74 Outstanding non-vested RSUs at September 30, 2024 7,449,922 $ 1.51
Stock-Based Compensation	The Company’s stock-based compensation is allocated to the following operating expense categories as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Research and development $ 754 $ 479 $ 2,012 $ 2,531 Selling, general and administrative 1,657 662 4,470 4,383 Total stock-based compensation $ 2,411 $ 1,141 $ 6,482 $ 6,914

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	The following table presents the calculations for the three and nine months ended September 30, 2024 and 2023 of basic and diluted net loss per share for the Company’s common stock (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Numerator Net loss $ (25,313) $ (24,728) $ (67,886) $ (73,912) Numerator for basic and diluted EPS - loss attributable to common stockholders $ (25,313) $ (24,728) $ (67,886) $ (73,912) Denominator Common stock 142,399 141,660 142,039 141,154 Denominator for basic and diluted EPS - weighted-average common stock 142,399 141,660 142,039 141,154 Basic and diluted net loss per share $ (0.18) $ (0.17) $ (0.48) $ (0.52)
Anti-Dilutive Common Equivalent Shares	The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive for the three and nine months ended September 30, 2024 and 2023 (in thousands) : September 30, 2024 2023 Outstanding options to purchase common stock 22,156,173 23,621,828 Outstanding restricted stock units 7,449,922 640,674 Outstanding warrants 3,968,319 3,968,319 33,574,414 28,230,821

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Costs	The Company’s restructuring costs, primarily for cash severance and other severance costs, are allocated to the following operating expense categories as follows (in thousands): Research and development Selling, general and administrative Total Balance as of December 31, 2023 $ 513 $ 6 $ 519 Restructuring charges incurred (1) 131 — 131 Cash payments and other adjustments (1) (422) (6) (428) Balance as of March 31, 2024 222 — 222 Cash payments and other adjustments (1) (216) — (216) Balance as of June 30, 2024 6 — 6 Cash payments and other adjustments (1) (6) — (6) Balance as of September 30, 2024 $ — $ — $ — Current liabilities $ — Long-term liabilities — Total liabilities as of September 30, 2024 $ — (1) Restructuring charges incurred and Cash payments and other adjustments include non-cash charges related to stock-based compensation expenses.

Organization and Description _2

Organization and Description of Business - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 563,520						$ 563,520		$ 495,634
Net loss	25,313	$ 23,099	$ 19,474	$ 24,728	$ 25,573	$ 23,611	67,886	$ 73,912
Cash, cash equivalents and investments in marketable securities	$ 196,300						$ 196,300

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Disaggregation of Revenue [Abstract]
Number of reportable segments | segment			1
Warranty period			1 year
Revenue:	$ 787	$ 223	$ 1,866	$ 682
Deferred revenue	$ 100		$ 100		$ 100
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Disaggregation of Revenue [Abstract]
Revenue, remaining performance obligation, percentage	38%		38%
Remaining performance obligation, expected timing of satisfaction	3 months		3 months
Domestic Sales
Disaggregation of Revenue [Abstract]
Revenue:	$ 400	200	$ 800	600
International Sales
Disaggregation of Revenue [Abstract]
Revenue:	$ 400	$ 0	$ 1,100	$ 100

Investments in Marketable Sec_3

Investments in Marketable Securities -Unrealized and Realized Gains/(Losses) and Dividend Income on Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Dividend income from marketable securities	$ 233	$ 2,572	$ 1,576	$ 7,274
Interest income from marketable securities	2,455	0	7,573	0
Unrealized gain on trading securities	0	1,953	0	8,302
Realized loss on trading securities	$ 0	$ (1,901)	$ 0	$ (6,489)

Investments in Marketable Sec_4

Investments in Marketable Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Amortized Costs	$ 153,914	$ 123,854
Gross Realized Gains	0
Gross Unrealized Gains	162	22
Gross Unrealized Losses		0
Fair Value	154,076	123,876
U.S. Treasury securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Costs	118,940	82,625
Gross Realized Gains	0
Gross Unrealized Gains	109	15
Gross Unrealized Losses		0
Fair Value	119,049	82,640
Commercial paper
Debt Securities, Available-for-Sale [Line Items]
Amortized Costs	34,974	41,229
Gross Realized Gains	0
Gross Unrealized Gains	53	7
Gross Unrealized Losses		0
Fair Value	$ 35,027	$ 41,236

Investments in Marketable Sec_5

Investments in Marketable Securities - Investments Classified by Contractual Maturity Date (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Held-to-Maturity Securities [Line Items]
One Year or Less	$ 154,076	$ 123,876
Over One Year Through Five Years	0	0
Over Five Years	0	0
Total	154,076	123,876
U.S. Treasury securities
Schedule of Held-to-Maturity Securities [Line Items]
One Year or Less	119,049	82,640
Over One Year Through Five Years	0	0
Over Five Years	0	0
Total	119,049	82,640
Commercial paper
Schedule of Held-to-Maturity Securities [Line Items]
One Year or Less	35,027	41,236
Over One Year Through Five Years	0	0
Over Five Years	0	0
Total	$ 35,027	$ 41,236

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Narrative (Details) - Private Warrants - Outstanding warrants	Sep. 30, 2024 $ / shares	Dec. 31, 2023 $ / shares
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	1.212	0.921
Risk-Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.037	0.0410
Strike Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	11.50	11.50
Share Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.88	2.01
Expected Life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Term of warrants	1 year 8 months 12 days	2 years 4 months 24 days

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Marketable securities	$ 154,076	$ 123,876
Total assets at fair value on a recurring basis	192,467
Warrant liabilities	357	1,274
Fair Value, Recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets at fair value on a recurring basis		253,192
Total liabilities at fair value on a recurring basis	357	1,274
Fair Value, Recurring | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	14,265	50,226
Fair Value, Recurring | U.S. Treasury securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:		59,654
Marketable securities	119,049	82,640
Fair Value, Recurring | Commercial paper
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	24,126	19,436
Marketable securities	35,027	41,236
Fair Value, Recurring | Public Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	345	1,227
Fair Value, Recurring | Private Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	12	47
Fair Value, Recurring | Level 1
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets at fair value on a recurring basis	38,391	192,520
Total liabilities at fair value on a recurring basis	345	1,227
Fair Value, Recurring | Level 1 | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	14,265	50,226
Fair Value, Recurring | Level 1 | U.S. Treasury securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:		59,654
Marketable securities	0	82,640
Fair Value, Recurring | Level 1 | Commercial paper
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	24,126	0
Marketable securities	0	0
Fair Value, Recurring | Level 1 | Public Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	345	1,227
Fair Value, Recurring | Level 1 | Private Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	0	0
Fair Value, Recurring | Level 2
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets at fair value on a recurring basis	154,076	60,672
Total liabilities at fair value on a recurring basis	0	0
Fair Value, Recurring | Level 2 | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	0	0
Fair Value, Recurring | Level 2 | U.S. Treasury securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:		0
Marketable securities	119,049	0
Fair Value, Recurring | Level 2 | Commercial paper
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	0	19,436
Marketable securities	35,027	41,236
Fair Value, Recurring | Level 2 | Public Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	0	0
Fair Value, Recurring | Level 2 | Private Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	0	0
Fair Value, Recurring | Level 3
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets at fair value on a recurring basis	0	0
Total liabilities at fair value on a recurring basis	12	47
Fair Value, Recurring | Level 3 | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	0	0
Fair Value, Recurring | Level 3 | U.S. Treasury securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:		0
Marketable securities	0	0
Fair Value, Recurring | Level 3 | Commercial paper
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash equivalents:	0	0
Marketable securities	0	0
Fair Value, Recurring | Level 3 | Public Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	0	0
Fair Value, Recurring | Level 3 | Private Warrants
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant liabilities	$ 12	$ 47

Inventory - Schedule of Net Inv

Inventory - Schedule of Net Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 1,666	$ 1,608
Work in progress	1,433	779
Finished goods	992	1,558
Total inventory	$ 4,091	$ 3,945

Inventory - Narrative (Details)

Inventory - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Inventory [Line Items]
Reserves against inventory	$ 0	$ 0	$ 0	$ 0
Research and development
Inventory [Line Items]
Reserves against inventory	$ 800		$ 2,400

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property and Equipment, Net [Abstract]
Subtotal	$ 29,661		$ 29,661		$ 26,318
Less: Accumulated depreciation and amortization	(13,407)		(13,407)		(10,043)
Property and equipment, net	16,254		16,254		16,275
Depreciation and amortization expense	1,200	$ 1,100	3,600	$ 2,900
Long-lived asset impairments	0	$ 0	0	$ 0
Laboratory and production equipment
Property and Equipment, Net [Abstract]
Subtotal	16,491		16,491		14,727
Computer equipment
Property and Equipment, Net [Abstract]
Subtotal	1,733		1,733		1,707
Purchased software
Property and Equipment, Net [Abstract]
Subtotal	188		188		188
Furniture and fixtures
Property and Equipment, Net [Abstract]
Subtotal	325		325		310
Leasehold improvements
Property and Equipment, Net [Abstract]
Subtotal	7,226		7,226		6,948
Construction in process
Property and Equipment, Net [Abstract]
Subtotal	$ 3,698		$ 3,698		$ 2,438

Leases - Lease-Related Costs (D

Leases - Lease-Related Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lease-Related Costs [Abstract]
Operating lease cost	$ 865	$ 864	$ 2,593	$ 2,613
Variable lease cost	497	545	1,325	1,226
Total lease cost	$ 1,362	$ 1,409	$ 3,918	$ 3,839

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Future Minimum Lease Payments [Abstract]
Remainder of 2024	$ 1,127
2025	4,527
2026	4,585
2027	4,549
2028	2,975
Thereafter	10,052
Total remaining undiscounted lease payments	27,815
Less: Imputed interest	(4,886)
Less: Lease incentives	(9,104)
Total lease liabilities	13,825
Less: current portion	(3,614)	$ (1,566)
Long-term operating lease liabilities	$ 10,211	$ 13,737
Weighted-average remaining lease term (in years)	5 years 9 months 18 days
Weighted-average discount rate	7.90%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Operating cash paid to settle operating lease liabilities	$ 3,310	$ 3,201
Right-of-use assets obtained in exchange for lease liabilities	$ 1,047	$ 83

Leases - Narrative (Details)

Leases - Narrative (Details) ft² in Thousands, $ in Thousands	1 Months Ended
	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($) ft²
Operating Lease, Description [Abstract]
Lease incentives	$ 9,104
Space Located in New Haven, Connecticut
Operating Lease, Description [Abstract]
Lease term			10 years
Area of leased space | ft²			67
Lease incentives			$ 9,100
Right of use asset, increase	1,000
Leasehold improvements	$ 1,200	$ 1,600

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]
Restructuring costs	$ 0	$ 519
Severance costs	206	0
Legal fees	1,008	979
Royalties	110	123
Other	1,515	194
Accrued expenses and other current liabilities	$ 2,839	$ 1,815

Stock-based Compensation - Narr

Stock-based Compensation - Narrative (Details) - USD ($) $ in Millions		1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 15, 2024	May 31, 2023	Nov. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 23, 2024	May 08, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Incremental stock-based compensation expense				$ 0.2	$ 0	$ 0.4	$ 0
Awarded November 9, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Granted (in shares)		1,000,000	2,780,000
Scenario, Plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense to be recognized	$ 2.4
Outstanding options to purchase common stock
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation related to stock options				1.7	1.1	$ 4.8	5.7
Granted (in shares)						2,282,600
Outstanding restricted stock units
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation				$ 0.7	$ 0	$ 1.7	$ 1.2
2021 Plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of shares available for grant (in shares)				13,204,915		13,204,915
2023 Inducement Plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of shares available for grant (in shares)				2,268,867		2,268,867
Capital shares reserved for future issuance (in shares)									3,000,000
Additional capital shares reserved for future issuance (in shares)								3,000,000

Stock-based Compensation - Fair

Stock-based Compensation - Fair Value of Each Stock Option Award (Details) - Share-Based Payment Arrangement, Employee	9 Months Ended
	Sep. 30, 2024 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield	0%
Weighted average grant date fair value per share (in usd per share)	$ 1.03
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	4 years 7 months 6 days
Risk-free interest rate	3.40%
Expected volatility	82.40%
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	5 years
Risk-free interest rate	5.20%
Expected volatility	90.60%

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Options (Details) - Outstanding options to purchase common stock $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Number of Options
Outstanding, beginning balance (in shares) | shares	22,511,900
Granted (in shares) | shares	2,282,600
Exercised (in shares) | shares	(137,539)
Forfeited (in shares) | shares	(2,385,526)
Expired (in shares) | shares	(115,262)
Outstanding, ending balance (in shares) | shares	22,156,173	22,511,900
Options exercisable (in shares) | shares	9,292,622
Vested and expected to vest (in shares) | shares	19,025,789
Weighted Average Exercise Price (per share)
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 2.79
Granted (in dollars per share) | $ / shares	1.51
Exercised (in dollars per share) | $ / shares	1
Forfeited (in dollars per share) | $ / shares	3.06
Expired (in dollars per share) | $ / shares	2.45
Outstanding, ending balance (in dollars per share) | $ / shares	2.64	$ 2.79
Options exercisable (in dollars per share) | $ / shares	3.27
Vested and expected to vest (in dollars per share) | $ / shares	$ 2.72
Weighted Average Remaining Contractual Term (in years)
Weighted Average Remaining Contractual Term (in years)	8 years	8 years 2 months 12 days
Options exercisable (in years)	6 years 9 months 18 days
Vested and expected to vest (in years)	7 years 9 months 18 days
Aggregate Intrinsic Value (in thousands)
Aggregate intrinsic value, outstanding, beginning balance | $	$ 3,194
Aggregate intrinsic value, outstanding, ending balance | $	51	$ 3,194
Options exercisable | $	51
Vested and expected to vest | $	$ 51

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - Outstanding restricted stock units	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Number of Shares Underlying RSUs
Outstanding non-vested RSUs, beginning balance (in shares) | shares	847,169
Granted (in shares) | shares	8,380,356
Vested (in shares) | shares	(805,396)
Forfeited (in shares) | shares	(972,207)
Outstanding non-vested RSUs, ending balance (in shares) | shares	7,449,922
Weighted Average Grant-Date Fair Value
Outstanding non-vested RSUs, beginning balance (in dollars per share) | $ / shares	$ 2.68
Granted (in dollars per share) | $ / shares	1.51
Vested (in dollars per share) | $ / shares	2.55
Forfeited (in dollars per share) | $ / shares	1.74
Outstanding non-vested RSUs, ending balance (in dollars per share) | $ / shares	$ 1.51

Stock-based Compensation - St_2

Stock-based Compensation - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock Options [Abstract]
Stock-based compensation	$ 2,411	$ 1,141	$ 6,482	$ 6,914
Research and development
Stock Options [Abstract]
Stock-based compensation	754	479	2,012	2,531
Selling, general and administrative
Stock Options [Abstract]
Stock-based compensation	$ 1,657	$ 662	$ 4,470	$ 4,383

Net Loss Per Share - Basic and

Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	$ (25,313)	$ (23,099)	$ (19,474)	$ (24,728)	$ (25,573)	$ (23,611)	$ (67,886)	$ (73,912)
Numerator for basic EPS - loss attributable to common stockholders	(25,313)			(24,728)			(67,886)	(73,912)
Numerator for diluted EPS - loss attributable to common stockholders	$ (25,313)			$ (24,728)			$ (67,886)	$ (73,912)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Common stock (in shares)	142,399			141,660			142,039	141,154
Denominator for basic EPS - weighted-average common stock (in shares)	142,399			141,660			142,039	141,154
Denominator for diluted EPS - weighted-average common stock (in shares)	142,399			141,660			142,039	141,154
Basic net loss per share (in dollars per share)	$ (0.18)			$ (0.17)			$ (0.48)	$ (0.52)
Diluted net loss per share (in dollars per share)	$ (0.18)			$ (0.17)			$ (0.48)	$ (0.52)

Net Loss Per Share -Anti-diluti

Net Loss Per Share -Anti-dilutive Common Equivalent Shares (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Loss per Share [Abstract]
Anti-dilutive common equivalent shares (in shares)	33,574,414	28,230,821	33,574,414	28,230,821
Outstanding options to purchase common stock
Net Loss per Share [Abstract]
Anti-dilutive common equivalent shares (in shares)	22,156,173	23,621,828	22,156,173	23,621,828
Outstanding restricted stock units
Net Loss per Share [Abstract]
Anti-dilutive common equivalent shares (in shares)	7,449,922	640,674	7,449,922	640,674
Outstanding warrants
Net Loss per Share [Abstract]
Anti-dilutive common equivalent shares (in shares)	3,968,319	3,968,319	3,968,319	3,968,319

Warrant Liabilities (Details)

Warrant Liabilities (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Warrants [Abstract]
Fair value of warrant liabilities	$ 357		$ 357		$ 1,274
Change in fair value of warrant liabilities	$ 121	$ (162)	$ 917	$ (81)
Public Warrants
Warrants [Abstract]
Outstanding public warrants	3,833,319		3,833,319		3,833,319
Number of shares of Class A common stock to be issued upon exercise of warrant (in shares)	1		1		1
Exercise price of warrant (in dollars per share)	$ 11.50		$ 11.50		$ 11.50
Warrant redemption price (in dollars per share)	0.01		$ 0.01
Notice period to redeem warrants			30 days
Threshold consecutive trading days			30 days
Share price (in dollars per share)	$ 18		$ 18
Threshold trading days			20 days
Period prior to notice of redemption			3 days
Trading day period to calculate fair market value over exercise price of warrants			10 days
Private Warrants
Warrants [Abstract]
Outstanding public warrants	135,000		135,000		135,000
Warrant redemption price (in dollars per share)	$ 0.01		$ 0.01
Limitation period to transfer, assign or sell warrants			30 days

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring liability	$ 0			$ 519
Restructuring [Roll Forward]
Restructuring reserve, beginning balance	6	$ 222	$ 519
Restructuring charges incurred			131
Cash payments and other adjustments	(6)	(216)	(428)
Restructuring reserve, ending balance	0	6	222
Restructuring liability	0			519
Long-term liabilities	0
Total Liabilities	0	6	222	519
Research and development
Restructuring [Roll Forward]
Restructuring reserve, beginning balance	6	222	513
Restructuring charges incurred			131
Cash payments and other adjustments	(6)	(216)	(422)
Restructuring reserve, ending balance	0	6	222
Total Liabilities	0	6	222	513
Selling, general and administrative
Restructuring [Roll Forward]
Restructuring reserve, beginning balance	0	0	6
Restructuring charges incurred			0
Cash payments and other adjustments	0	0	(6)
Restructuring reserve, ending balance	0	0	0
Total Liabilities	$ 0	$ 0	$ 0	$ 6

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Estimated annual effective tax rate	(0.17%)	0%	(0.06%)	0%

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Dr. Rothberg | 2021 Plan
Related Party Transaction [Line Items]
Number of shares that can be purchased with option granted (in shares)	250,000
4C | Monthly Services Under Amended and Restated Technology Services Agreement | Related Party
Related Party Transaction [Line Items]
Operating expenses		$ 0.1	$ 0.1
4C | Month-to-Month Sublease Arrangements for Office and Laboratory Spaces | Related Party
Related Party Transaction [Line Items]
Operating expenses				$ 0.2	$ 0.3
PEI | New Collaboration | Related Party
Related Party Transaction [Line Items]
Due from related parties						$ 0.3

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Other Commitments [Abstract]
Employer matching contributions to 401(k) plan	$ 0	$ 0	$ 0	$ 0
Licenses Related to Certain Intellectual Property
Licenses Related to Certain Intellectual Property [Abstract]
Annual minimum fixed payments	100		100
Accrued payments	$ 100		$ 100		$ 100